GenoSafe

GenoSafe is a biotechnology startup that positions itself as a bioanalytical CRO partner for gene and cell therapies. With the slogan "Your bioanalytical CRO partner for Gene and Cell Therapies," GenoSafe offers analytical testing services for the evaluation of the quality, safety, and efficacy of gene and cell therapy candidates. This includes GLP biodistribution, shedding, and immunogenicity studies, as well as QC testing such as viral titration, safety, and potency/efficacy testing, and GCP bioanalysis of patient samples, encompassing immunogenicity, shedding, and gene expression studies. Founded in 2003, GenoSafe boasts over 15 years of experience in the development, qualification, and validation of key analytical methods for product and sample testing. The startup has carved its niche in the biotechnology industry by specializing in services critical to the advancement of gene and cell therapies. Despite the absence of specific information on headquarters, last investment, or last investment investors, GenoSafe's stronghold in the biotechnology sector and its specific focus on crucial analytical testing services for gene and cell therapy candidates make it a potential point of interest for venture capital firms seeking opportunities in the biotechnology space. With its established expertise and strong positioning, GenoSafe presents itself as a potential prospect for investment within the biotech sector.